Withaferin A

Antitumor activity of withaferin A (NSC-101088): B. Shohat, et al.; Cancer Chemother. Rep. 51, 271 (1967) | Withaferin A is a potent inhibitor of angiogenesis: R. Mohan, et al.; Angiogenesis 7, 115 (2004) | Neuritic regeneration and synaptic reconstruction induced by withanolide: A: T. Kuboyama, et al.; Br. J. Pharmacol. 144, 961 (2005) | The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from "Indian winter cherry": H. Yang, et al.; Mol. Pharmacol. 71, 426 (2007) | The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin: P. Bargagna-Mohan, etal.; Chem. Biol. 14, 623 (2007) | Withaferin A induces apoptosis by activating p38 mitogen-activated protein kinase signaling cascade in leukemic cells of lymphoid and myeloid origin through mitochondrial death cascade: C. Mandal, et al.; Apoptosis 13, 1450 (2008) | Inhibition of monosodium urate crystal-induced inflammation by withaferin A: E.P. Sabina, et al.; J. Pharm. Pharm. Sci. 11, 46 (2008) | Withaferin A targets heat shock protein 90 in pancreatic cancer cells: Y. Yu, et al.; Biochem. Pharmacol. 79, 542 (2010) | Notch-1 inhibition by Withaferin-A: a therapeutic target against colon carcinogenesis: S. Koduru, et al.; Mol. Cancer Ther. 9, 202 (2010) | Withaferin A inhibits activation of signal transducer and activator of transcription 3 in human breast cancer cells: J. Lee, et al.; Carcinogenesis. 31, 1991 (2010) | Inhibition of the NEMO/IKK? association complex formation, a novel mechanism associated with the NF-kB activation suppression by Withania somnifera's key metabolite withaferin A: A. Grover, et al.; BMC Genomics 11, s25 (2010) | Withaferin A induces apoptosis in human melanoma cells through generation of reactive oxygen species and down-regulation of Bcl-2: E. Mayola, et al.; Apoptosis 16, 1014 (2011) | Withaferin a alters intermediate filament organization, cell shape and behavior: B. Grin, et al.; PLoS One 7, e39065 (2012) | Withaferin A causes activation of Notch2 and Notch4 in human breast cancer cells: J. Lee, et al.; Breast Cancer Res. Treat. 136, 45 (2012) | Molecular insight in the multifunctional activities of Withaferin A: W. Van den Berghe, et al.; Biochem. Pharmacol. 84, 1282 (2012) (Review) | Inhibition of VEGF: a novel mechanism to control angiogenesis by Withania somnifera's key metabolite Withaferin A: S. Saha, et al.; In Silico Pharmacol. 1, 11 (2013) | Withaferin A inhibits NF-kappaB activation by targeting cysteine 179 in IKK?: K. Heyninck, et al.; Biochem. Pharmacol. 91, 501 (2014) | Withaferin A Inhibits Helicobacter pylori-induced Production of IL-1beta in Dendritic Cells by Regulating NF-kappaB and NLRP3 Inflammasome Activation: J.E. Kim, et al.; Immune Netw. 15, 269 (2015) | Molecular docking and dynamic simulation studies evidenced plausible immunotherapeutic anticancer property by Withaferin A targeting indoleamine 2,3-dioxygenase: S.V. Reddy, et al.; J. Biomol. Struct. Dyn. 33, 2695 (2015) | Hedgehog inhibitors from Withania somnifera: T. Yoneyama, et al.; Bioorg. Med. Chem. Lett. 25, 3541 (2015) | The Use of Withaferin A to study intermediate filaments: R. Mohan & P. Bargagna-Mohan; Methods Enzymol. 568, 187 (2016) | Simultaneous inhibition of the ubiquitin-proteasome system and autophagy enhances apoptosis induced by ER stress aggravators in human pancreatic cancer cells: Autophagy 12, 1521 (2016) | Withaferin A is a leptin sensitizer with strong antidiabetic properties in mice: J. Lee, et al.; Nat. Med. 22, 1023 (2016) | Withaferin-A - A natural anticancer agent with pleitropic mechanisms of action: I.C. Lee & B.Y. Choi; Int. J. Mol. Sci. 17, 290 (2016) (Review)